| Income statement (USD) | Q2 2025 ended Jun 30, 2025 | Q2 2025 ended Mar 31, 2025 | Q2 2024 ended Jun 30, 2024 | Q2 2024 ended Mar 31, 2024 | Q2 2023 ended Jun 30, 2023 | Q1 2023 ended Mar 31, 2023 | Q4 2022 ended Dec 31, 2022 | Q3 2022 ended Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 2.93M | 5.02M | 6.89M | 5.89M | 5.42M | |||
| Operating expenses | 3.77M | 8.20M | 9.05M | 8.64M | 8.32M | |||
| Income before tax | -3.63M | -7.94M | -8.73M | -8.26M | -8.08M | |||
| Income tax | 0 | 34.0K | 21.0K | 10.0K | 0 | |||
| Net income | -2.06M | -3.32M | -3.63M | -3.87M | -7.97M | -8.75M | -8.27M | -8.08M |
| EPS | 0.01 | 0.04 | 0.04 | 0.04 | 0.04 | |||
| EPS (diluted) | 0.01 | 0.04 | 0.04 | 0.04 | 0.04 | |||
| Diluted shares | 286.08M | 221.67M | 221.00M | -759.8K | 228.77M |
From Chemomab Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.